# ClavystBio

> ClavystBio is a VC fund in Singapore backing Biotechnology and Health Care. See 15 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Singapore, Singapore
- Total investments: 15
- Last investment: Jun 2026
- Lead investor: 53%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/clavystbio/
- Website: https://www.clavystbio.com/

ClavystBio is a VC fund in Singapore focused on Biotechnology and Health Care. ClavystBio invest in early-stage ventures in the biotech, medTech, and digital health sectors, as well as in real estate and services.

## Contacts

5 contacts available for ClavystBio. Shizune tracks 1 team members at ClavystBio. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/clavystbio?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $12M–$187M |
| Venture - Series Unknown | $14M–$25M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 10 | 67% |
| Health Care | 8 | 53% |
| Medical | 5 | 33% |
| Therapeutics | 3 | 20% |
| Medical Device | 2 | 13% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 33% |
| Venture - Series Unknown | 3 | 20% |
| Seed | 2 | 13% |
| Series B | 2 | 13% |
| Series C | 1 | 7% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Singapore | 7 | 47% |
| United States | 4 | 27% |
| The Netherlands | 1 | 7% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Sang Shin | Director, Digital Health | 0 | https://shizune.co/investors/profile/sang-shin |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Leyden Labs | Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains ofrespiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. | $45.4M |  | Jun 25, 2026 |  |
| Rejoni | Rejoni uses bio-materials to develop medical devices that improve the outcome of minimally invasive and gynecological surgical procedures. | $25M | Venture - Series Unknown | Jun 16, 2026 |  |
| Biobot Surgical Pte Ltd | Biobot Surgical is a global technology provider in minimally-invasive robotic healthcare solutions. | $7.8M | Series C | Apr 09, 2026 |  |
| Cirrus Therapeutics | Cirrus Therapeutics is a Biotechnology Research firm diganosing and treating eye diseases affecting ocular immune system. | $11M | Seed | Aug 19, 2025 |  |
| Respiree | They offer platforms that are able to report clinical deterioration and provide recommended interventions with post-monitoring.They work in the health care industry, just like you. We take the time to get to know you, and we always keep your best interests in mind when adding and adjusting products in our catalog. | $11.6M | Series A | Jul 23, 2025 |  |
| Allay Therapeutics | Allay Therapeutics offers analgesic products for post-surgical pain management and recuperation. The company was founded in 2017 and is headquartered in Menlo Park, California, United States. | $57.5M | Series D | Jun 05, 2025 |  |
| Nuevocor | Nuevocor is a preclinical-stage biopharmaceutical company focused on developing gene therapy‑based treatments that have the potential to restore cardiac function in diseased hearts. | $45M | Series B | May 06, 2025 |  |
| Callio Therapeutics | Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits. | $187M | Series A | Mar 03, 2025 |  |
| Leyden Labs | Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains ofrespiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. | $70M | Series B | Jan 09, 2025 |  |
| Sunbird Bio | Sunbird Bio is a diagnostics platform developer that aims to give molecular diagnostics with faster outcomes. Sunbird Bio was founded by Huilin Shao. | $14M | Venture - Series Unknown | Oct 16, 2024 |  |

10 of 15 investments shown.

## Co-investors
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund, 6 deals together
- [Polaris Partners](https://shizune.co/investors/profile/polaris-partners) — VC Fund, 6 deals together
- [Seeds Capital](https://shizune.co/investors/profile/seeds-capital) — VC Fund, 5 deals together
- [Accelerator Life Science Partners](https://shizune.co/investors/profile/accelerator-life-science-partners) — VC Fund, 3 deals together
- [Leaps by Bayer](https://shizune.co/investors/profile/leaps-by-bayer) — VC Fund, 3 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Everywhere Ventures](https://shizune.co/investors/profile/everywhere-ventures) — VC Fund
- [Andreessen Horowitz](https://shizune.co/investors/profile/andreessen-horowitz) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Seeds Capital](https://shizune.co/investors/profile/seeds-capital) — VC Fund
- [Wavemaker Ventures](https://shizune.co/investors/profile/wavemaker-partners) — VC Fund

## Featured in investor lists
- [Health Care VC Funds in Singapore](https://shizune.co/investors/health-care-vc-funds-singapore)
- [Health Care Investors in Singapore](https://shizune.co/investors/health-care-investors-singapore)
- [Biotechnology VC Funds in Singapore](https://shizune.co/investors/biotechnology-vc-funds-singapore)
- [Biotech VC Funds in Singapore](https://shizune.co/investors/biotech-vc-funds-singapore)
- [Biotechnology Investors in Singapore](https://shizune.co/investors/biotechnology-investors-singapore)
- [Biotech Investors in Singapore](https://shizune.co/investors/biotech-investors-singapore)

## FAQ

### What does ClavystBio invest in?

ClavystBio invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Venture - Series Unknown stage. Most of the 15 investments tracked by Shizune back companies in Singapore. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is ClavystBio's check size?

ClavystBio typically joins rounds of $12M–$187M at Series A and $14M–$25M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds ClavystBio participates in.

### How do I contact ClavystBio?

Public channels for ClavystBio include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at ClavystBio?

The team at ClavystBio includes Sang Shin (Director, Digital Health). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co